The international clinical study, Bio-Hermes-002, establishes an
ambitious transnational collaboration aimed at achieving a
breakthrough in Alzheimer's diagnosis and treatment.
LONDON and ROCHESTER, N.Y., July 31,
2024 /PRNewswire/ -- iLoF, a global deep tech digital
health company, today announced it has secured a £1.2M
(~$1.5M) clinical research contract
from Innovate UK, the UK's national innovation agency. This
funding, awarded through Innovate UK's Contracts for Innovation
initiative, will enable iLoF to deploy its AI-powered Optomics®
platform in Bio-Hermes-002, a landmark transnational study aimed at
revolutionizing Alzheimer's disease research and treatment.
The Contracts for Innovation program supports public sector
organizations in addressing complex challenges by funding new
solutions and technologies. iLoF is one of the few leading
companies that will deploy its platform technologies to
Bio-Hermes-002, positioning the study as the most ambitious
transnational initiative in Alzheimer's research to date.
Led by the Global Alzheimer's Platform Foundation® (GAP), a US
patient-centric organization dedicated to accelerating the delivery
of innovative therapies for neurological disorders, Bio-Hermes-002
is a landmark clinical research project spanning the United States, Canada, and the United Kingdom. This ambitious study aims to
evaluate innovative technologies with over 1,000 participants,
using blood-based and digital biomarkers to revolutionize our
understanding of Alzheimer's disease.
iLoF's contribution to this groundbreaking study centres on its
Optomics® platform, an AI-powered technology that combines
photonics and multimodal data analysis. This innovative approach
generates biomarkers through a non-invasive, scalable, and
streamlined process, leveraging massive amounts of data to provide
rigorous and tailored information to enhance patient
stratification, reduce screen failures and improve the efficiency
of Alzheimer's research.
"We are extremely honored to be part of this leading study. This
contract is crucial for advancing the deployment and adoption of
Optomics®," says Mehak Mumtaz, iLoF's COO. Luís Valente, iLoF's
CEO, considers access to this dataset "a unique opportunity of
vital importance for expanding our growing library of biological
profiles. The goal is to further enhance sensitivity to a broader
range of profiles, enabling it to address bigger, more complex
challenges, increasing our impact in the fight against
Alzheimer's."
President of the Global Alzheimer's Platform, John Dwyer, said: "It is an important
advancement of the field that our transatlantic collaboration will
facilitate iLoF, one of the UK's leading AD emerging technology
companies, to participate in Bio-Hermes-002, which will contribute
to improving research for diagnosing and treating this pernicious
disease. Thanks to our partnership with Innovate UK, we are
confident that iLof will advance our collective ability to better
diagnose and treat Alzheimer's disease for patients around the
world."
Towards the study, iLoF's US operation will be supported by
Luminate—the world's largest accelerator for startups specializing
in optics, providing strategic capital and access to
state-of-the-art lab facilities in Rochester, further advancing the platform
deployed in the study.
According to the WHO, Alzheimer's affects more than 55 million
people worldwide. iLoF supports personalized drug development to
various core conditions, unlocking novel data dimensions while
delivering precise insights that accelerate both clinical and
pre-clinical development.
About iLoF
iLoF is a deep tech, digital health company pioneering
Optomics®: a breakthrough Al-platform designed to accelerate the
future of personalized medicine, ingesting massive amounts of data
to build a comprehensive digital library of biomarkers and
biological profiles.
Recognized by CB Insights as one of the top Digital Health
companies in the world and by the Financial Times as a
Transformational Business in Healthcare, iLoF is supported by
leading investors like Microsoft Ventures, Lunar Ventures, or
Faber.
For more details: www.ilof.tech
Contact:
Filipa Magalhães de Rooij
381148@email4pr.com
Tel: +351 938 828 835
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ilof-secures-1-5m-clinical-research-contract-to-deploy-its-optomics-platform-in-leading-international-alzheimers-study-and-expands-into-the-us-302211134.html
SOURCE iLoF